Gilead Sciences broke ground on its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center (NTDC) at the company’s Foster City headquarters in California. This milestone marks continued momentum in Gilead’s multi-year strategy to drive growth and scientific leadership across virology, oncology, and inflammation, increasingly built on growing biologics capabilities, according to Daniel O’Day, chairman and CEO.

“This new facility is part of our vision for delivering next generation therapies and a cornerstone of Gilead’s $32 billion investment commitment in the United States,” said O’Day. “We have multiple construction projects underway, all of which will generate thousands of American jobs and help to drive U.S. leadership in global biopharma innovation.”

The five-story, 180,000-sq-foot facility will serve as a hub for innovation and collaboration across technical development and manufacturing teams. Designed with flexible pilot lab space and advanced digital infrastructure, the NTDC will accelerate technology transfer and support the advancement of next-generation biologics across Gilead’s pipeline, predicts O’Day, adding that the facility will strengthen Gilead’s biologics capacity and capabilities. It will feature digitally enabled systems, autonomous robotics, and real-time digital monitoring.

This groundbreaking is part of a broader expansion at Gilead’s Foster City headquarters. In addition to the NTDC, the company is currently developing two others: a new research building designed to accelerate scientific discovery, already under construction, and a biologics manufacturing facility that will expand domestic production capacity. These current investments further build on Gilead’s strong history of U.S. investment, with more than $15 billion over the last decade, pointed out O’Day.